188 related articles for article (PubMed ID: 22697462)
1. B-cell depletion therapy in patients with diffuse systemic sclerosis associates with a significant decrease in PDGFR expression and activation in spindle-like cells in the skin.
Daoussis D; Tsamandas AC; Liossis SN; Antonopoulos I; Karatza E; Yiannopoulos G; Andonopoulos AP
Arthritis Res Ther; 2012 Jun; 14(3):R145. PubMed ID: 22697462
[TBL] [Abstract][Full Text] [Related]
2. B cell depletion therapy upregulates Dkk-1 skin expression in patients with systemic sclerosis: association with enhanced resolution of skin fibrosis.
Daoussis D; Tsamandas A; Antonopoulos I; Filippopoulou A; Papachristou DJ; Papachristou NI; Andonopoulos AP; Liossis SN
Arthritis Res Ther; 2016 May; 18(1):118. PubMed ID: 27208972
[TBL] [Abstract][Full Text] [Related]
3. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Kazantzi A; Sirinian C; Karampetsou M; Yiannopoulos G; Andonopoulos AP
Rheumatology (Oxford); 2010 Feb; 49(2):271-80. PubMed ID: 19447770
[TBL] [Abstract][Full Text] [Related]
4. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
[TBL] [Abstract][Full Text] [Related]
5. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis.
Daoussis D; Liossis SN; Tsamandas AC; Kalogeropoulou C; Paliogianni F; Sirinian C; Yiannopoulos G; Andonopoulos AP
Clin Exp Rheumatol; 2012; 30(2 Suppl 71):S17-22. PubMed ID: 22244622
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in diffuse cutaneous systemic sclerosis: should we be using it today?
McQueen FM; Solanki K
Rheumatology (Oxford); 2015 May; 54(5):757-67. PubMed ID: 25573841
[TBL] [Abstract][Full Text] [Related]
8. Role of PDGFs/PDGFRs signaling pathway in myocardial fibrosis of DOCA/salt hypertensive rats.
Fan B; Ma L; Li Q; Wang L; Zhou J; Wu J
Int J Clin Exp Pathol; 2014; 7(1):16-27. PubMed ID: 24427322
[TBL] [Abstract][Full Text] [Related]
9. Alteration of circulating miRNAs in SSc: miR-30b regulates the expression of PDGF receptor β.
Tanaka S; Suto A; Ikeda K; Sanayama Y; Nakagomi D; Iwamoto T; Suzuki K; Kambe N; Matsue H; Matsumura R; Kashiwakuma D; Iwamoto I; Nakajima H
Rheumatology (Oxford); 2013 Nov; 52(11):1963-72. PubMed ID: 23893664
[TBL] [Abstract][Full Text] [Related]
10. Lack of detection of agonist activity by antibodies to platelet-derived growth factor receptor alpha in a subset of normal and systemic sclerosis patient sera.
Loizos N; Lariccia L; Weiner J; Griffith H; Boin F; Hummers L; Wigley F; Kussie P
Arthritis Rheum; 2009 Apr; 60(4):1145-51. PubMed ID: 19333919
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study.
Campochiaro C; De Luca G; Lazzaroni MG; Zanatta E; Bosello SL; De Santis M; Cariddi A; Bruni C; Selmi C; Gremese E; Matucci-Cerinic M; Doria A; Airò P; Dagna L
Rheumatology (Oxford); 2020 Dec; 59(12):3731-3736. PubMed ID: 32413118
[TBL] [Abstract][Full Text] [Related]
12. Lipoic acid plays a role in scleroderma: insights obtained from scleroderma dermal fibroblasts.
Tsou PS; Balogh B; Pinney AJ; Zakhem G; Lozier A; Amin MA; Stinson WA; Schiopu E; Khanna D; Fox DA; Koch AE
Arthritis Res Ther; 2014; 16(5):411. PubMed ID: 25123250
[TBL] [Abstract][Full Text] [Related]
13. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
[TBL] [Abstract][Full Text] [Related]
14. Reduced type I collagen gene expression by skin fibroblasts of patients with systemic sclerosis after one treatment course with rituximab.
Fraticelli P; De Vita S; Franzolini N; Svegliati S; Scott CA; Tonnini C; Spadoni T; Gabrielli B; Pomponio G; Moroncini G; Gabrielli A
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S160-7. PubMed ID: 26339895
[TBL] [Abstract][Full Text] [Related]
15. Lack of evidence of stimulatory autoantibodies to platelet-derived growth factor receptor in patients with systemic sclerosis.
Classen JF; Henrohn D; Rorsman F; Lennartsson J; Lauwerys BR; Wikström G; Rorsman C; Lenglez S; Franck-Larsson K; Tomasi JP; Kämpe O; Vanthuyne M; Houssiau FA; Demoulin JB
Arthritis Rheum; 2009 Apr; 60(4):1137-44. PubMed ID: 19333949
[TBL] [Abstract][Full Text] [Related]
16. Neer Award 2018: Platelet-derived growth factor receptor α co-expression typifies a subset of platelet-derived growth factor receptor β-positive progenitor cells that contribute to fatty degeneration and fibrosis of the murine rotator cuff.
Jensen AR; Kelley BV; Mosich GM; Ariniello A; Eliasberg CD; Vu B; Shah P; Devana SK; Murray IR; Péault B; Dar A; Petrigliano FA
J Shoulder Elbow Surg; 2018 Jul; 27(7):1149-1161. PubMed ID: 29653843
[TBL] [Abstract][Full Text] [Related]
17. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement.
Smith V; Piette Y; van Praet JT; Decuman S; Deschepper E; Elewaut D; De Keyser F
J Rheumatol; 2013 Jan; 40(1):52-7. PubMed ID: 23118116
[TBL] [Abstract][Full Text] [Related]
18. Molecular framework for response to imatinib mesylate in systemic sclerosis.
Chung L; Fiorentino DF; Benbarak MJ; Adler AS; Mariano MM; Paniagua RT; Milano A; Connolly MK; Ratiner BD; Wiskocil RL; Whitfield ML; Chang HY; Robinson WH
Arthritis Rheum; 2009 Feb; 60(2):584-91. PubMed ID: 19180499
[TBL] [Abstract][Full Text] [Related]
19. Expression of platelet-derived growth factor receptor in low-grade endometrial stromal sarcomas in the absence of activating mutations.
Liegl B; Gülly C; Reich O; Nogales FF; Beham A; Regauer S
Histopathology; 2007 Mar; 50(4):448-52. PubMed ID: 17448020
[TBL] [Abstract][Full Text] [Related]
20. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis.
Lafyatis R; Kissin E; York M; Farina G; Viger K; Fritzler MJ; Merkel PA; Simms RW
Arthritis Rheum; 2009 Feb; 60(2):578-83. PubMed ID: 19180481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]